A 2023 trial in patients with fatty liver disease went further, showing that semaglutide decreased both VAT and hepatic fat, underscoring how central fat loss links directly to organ health
The announcement builds on work Cigna has already done through its EncircleRx product, which was launched under its Express Scripts unit in response to the challenges clients faced around the GLP-1 class
Keel PK, Bodell LP, Forney KJ, Appelbaum J, Williams D
You may experience fatigue, poor detoxification, higher oxidative stress, and greater vulnerability to chronic illness
Weight-loss results are self-reported, not typical, and vary based on starting weight, adherence, and individual health